Abstract:Han Li, 1, &ast Yinan Ding, 2, &ast Jiayan Huang, 1 Yanyan Zhao, 1 Wei Chen, 3 Qiusha Tang, 2 Yanli An, 4 Rong Chen, 5 Chunmei Hu 1 1 Department of Tuberculosis, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; 2 Medical School of Southeast University, Nanjing, People's Republic of China; 3 Department of Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; 4 Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, People's Republic of China; 5 Department of Oncology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chunmei Hu, Department of tuberculosis, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210009, People's Republic of China, Email Background: Central nervous system tuberculosis (CNS-TB) is the most devastating form of extrapulmonary tuberculosis. Rifampin (RIF) is a first-line antimicrobial agent with potent bactericidal action. Nonetheless, the blood-brain barrier (BBB) limits the therapeutic effects on CNS-TB. Exosomes, however, can facilitate drug movements across the BBB. In addition, exosomes show high biocompatibility and drug-loading capacity. They can also be modified to increase drug delivery efficacy. In this study, we loaded RIF into exosomes and modified the exosomes with a brain-targeting peptide to improve BBB permeability of RIF; we named these exosomes ANG-Exo-RIF. Methods: Exosomes were isolated from the culture medium of BMSCs by differential ultracentrifugation and loaded RIF by electroporation and modified ANG by chemical reaction. To characterize ANG-Exo-RIF, Western blot (WB), nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM) were performed. Bend.3 cells were incubated with DiI labeled ANG-Exo-RIF and then fluorescent microscopy and flow cytometry were used to evaluate the targeting ability of ANG-Exo-RIF in vitro. Fluorescence imaging and frozen section were used to evaluate the targeting ability of ANG-Exo-RIF in vivo. MIC and MBC were determined through microplate alamar blue assay (MABA). Results: A novel exosome-based nanoparticle was developed. Compared with untargeted exosomes, the targeted exosomes exhibited high targeting capacity and permeability in vitro and in vivo. The MIC and MBC of ANG-Exo-RIF were 0.25 μg/mL, which were sufficient to meet the clinical needs. Conclusion: In summary, excellent targeting ability, high antitubercular activity and biocompatibility endow ANG-Exo-RIF with potential for use in future translation-aimed research and provide hope for an effective CNS-TB treatment. Graphical Keywords: exosome, central nervous system tuberculosis, blood-brain barrier, rifampin Graphical Tuberculosis (TB) is an infectious disease caused by a mycobacterial infection. Central nervous system tuberculosis (CNS-TB) is the most devastating form of extrapulmonary tuberculosis with high mortality and disability rates. 1,2 For example, tuberculous meningitis, a kind of CNS-TB, can lead to the death or neurological sequelae in one-half of the patients infected, including those taking anti-tuberculosis therapy. 3 Rifampin (RIF), an inhibitor of DNA-dependent RNA polymerase, exhibits excellent antibacterial ability as a first-line TB drug. 4 However, the blood-brain barrier (BBB) limits its permeability into affected areas. 1,5 At the recommended dose of RIF, the ratio of the drug concentration in CSF to that in serum is 0.04–0.11; in the CSF, RIF at this concentration barely reaches the minimum inhibitory concentration (MIC) against mycobacterium tuberculosis. 6 This indicates that the existence of the BBB leads to the low drug concentration in the brain, which greatly reduces the therapeutic efficiency. Therefore, improving the drug's ability to penetrate the BBB may be a promising and effective way to improve RIF-based therapy in CNS-TB. 7 Recently, the strategy of nano-based drug delivery has been developed. 8 Although the nano-based drug delivery systems can improve the therapeutic efficacy of drugs, the biosafety of the nanomaterials used for this purpose cannot be ignored. 9 Therefore, better drug carriers need to be explored. Exosomes, with a size range of 40–160nm, are lipid bilay -Abstract Truncated-

Angiopep-2 Modified Exosomes Load Rifampicin with Potential for Treating Central Nervous System Tuberculosis

Long-acting Antituberculous Therapeutic Nanoparticles Target Macrophage Endosomes.

Effective cerebral tuberculosis treatment via nose-to-brain transport of anti-TB drugs using mucoadhesive nano-aggregates

Genipin-crosslinked Carboxymethyl Chitosan Nanogel for Lung-Targeted Delivery of Isoniazid and Rifampin.

Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy

Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant Mycobacterium tuberculosis

Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain

Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel

Navigating the Blood-Brain Barrier: An Anti-CD19 Modified-Exosome Delivery System for Precise Targeting of CNS Lymphoma

Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

Targeted Theranostics for Tuberculosis: A Rifampicin-Loaded Aggregation-Induced Emission Carrier for Granulomas Tracking and Anti-Infection.

Mannosylated Graphene Oxide As Macrophage-Targeted Delivery System for Enhanced Intracellular M.tuberculosis Killing Efficiency.

An aerosol nanocomposite microparticle formulation using rifampicin-cyclodextrin inclusion complexes for the treatment of pulmonary diseases

Anti-transferrin Receptor-Modified Amphotericin B-loaded PLA-PEG Nanoparticles Cure Candidal Meningitis and Reduce Drug Toxicity.

Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Macrophage Targeted Iron Oxide Nanodecoys Augment Innate Immunological and Drug Killings for More Effective Mycobacterium Tuberculosis Clearance.

Isoniazid nano-drug delivery systems targeting macrophages for the treatment of tuberculosis

Transport of Mir-766-3p to A549 Cells by Plasma-Derived Exosomes and Its Effect on Intracellular Survival of Mycobacterium Tuberculosis by Regulating NRAMP1 Expression in A549 Cells

Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis

Novel Targeting Of Pegylated Liposomes For Codelivery Of Tgf-Beta I Sirna And Four Antitubercular Drugs To Human Macrophages For The Treatment Of Mycobacterial Infection:A Quantitative Proteomic Study

Rifampicin‐Loaded Nano‐In‐Microparticles (Trojan Particles) As A Pulmonary Delivery System For Tuberculosis Treatment